Hannah Hazard-Jenkins named director of WVU Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hannah Hazard-Jenkins, associate chair of surgery for cancer services, was named the permanent director of the WVU Cancer Institute after having served in the position on an interim basis since January.

“I have been and will always be committed to ensuring that everyone who seeks us out for care has access to the latest advancements in treatment, procedures, and clinical trials regardless of where they come into our system—whether it’s at our flagship campus in Morgantown or one of our regional sites,” Hazard-Jenkins said in a statement.

As the director of clinical services for the WVU Cancer Institute’s Mary Babb Randolph Cancer Center, Hazard-Jenkins helped manage clinical affairs and programmatic development, as well as the institute’s statewide network of cancer care. She also serves as the director of the institute’s Comprehensive Breast Cancer Program and as chief of staff at WVU Medicine J.W. Ruby Memorial Hospital.

Table of Contents


With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).